The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.63 per share a year ago.
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?